Pimecrolimus (SDZ ASM 981): Current state of research;Pimecrolimus (SDZ ASM 981): Aktueller stand der forschung

Deutsche Medizinische Wochenschrift

Volumn 127, Issue 22, 2002, Pages 1199-1203

  Dissemond, Joachim ^a   Goos, M ^a   Wagner, S N ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADZ ASM 981; CALCINEURIN; CLOBETASOL PROPIONATE; CYCLOPHILIN; CYCLOSPORIN; CYCLOSPORIN A; INTERLEUKIN 2; PIMECROLIMUS; TOLNAFTATE;

ANTIINFLAMMATORY ACTIVITY; ATOPIC DERMATITIS; CLINICAL RESEARCH; CLINICAL TRIAL; CYTOKINE RELEASE; DRUG ACTIVITY; DRUG EFFICACY; DRUG FORMULATION; DRUG RESEARCH; DRUG STABILITY; DRUG STRUCTURE; DRUG TOLERABILITY; HUMAN; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; PATHOPHYSIOLOGY; REVIEW;

ADMINISTRATION, CUTANEOUS; ADULT; ANIMALS; CHILD; DERMATOLOGIC AGENTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNOSUPPRESSIVE AGENTS; SKIN; SKIN DISEASES; TACROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 0037205316     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-31941     Document Type: Review

References (22)

1. Calcineurin inhibitors FK506 and SDZ ASM 981 alleviate the outcome of focal cerebral ischemic/reperfusion injury
2. Macrolactam immunomodulators for topical treatment of inflammatory skin diseases
3. Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A
4. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: In vitro pharmacology
5. First experience of topical SDZ ASM 981 in children with atopic dermatitis
6. Ascomycin macrolactam derivative SDZ ASM 981 inhibits the release of granule-associated mediators and of newly synthesized Cytokines in RBL 2H3 mast cells in an immunophilin-dependent manner
7. Structure-function relationships in the FK506-binding protein (FKBP) family of peptidylprolyl cis-trans isomerases
8. FK506 and cyclosporin, molecular probes for studying intracellular signal transduction
9. SDZ ASM 981: An emerging safe and effective treatment for atopic dermatitis
10. Treatment of immune-mediated skin diseases: Future perspectives
11. A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: In vivo pharmacology
12. The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion
13. Atopic dermatitis-like symptoms in hypomagnesaemic hairless rats are prevented and inhibited by systemic or topical SDZ ASM 981
14. Ascomycins: Promising agents for the treatment of inflammatory skin diseases
15. SDZ ASM 981 is the first non-steroid that suppresses established nickel contact dermatitis elicited by allergen challenge
16. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: A randomized, double-blind controlled study
17. Clearing of psoriasis by a novel immunsuppressive macrolide
18. Oral SDZ ASM 981: Safety, pharmacokinetics and efficacy in patients with moderate to severe chronic plaque psoriasis
19. Acquired scalp alopecia. Part II: A review
20. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis
21. Low systemic concentrations of SDZ ASM 981 after topical treatment of extensive atopic dermatits lesions
22. The ascomycin macrolactam pimecrolimus (Elidel, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils